A Randomized Study to Compare Post-transplant Cyclophosphamide, Sirolimus, Ruxolitinib and Post-transplant Cyclophosphamide, Sirolimus, Mycophenolate Mofetil to Prevent Graft Versus Host Disease

Primary Objective: To compare Grade 2-4 acute graft versus host disease-free survival (GFS) between the MMF and Ruxolitinib arms Secondary Objectives: To compare the following between treatment arms: 1. Grade 3-5 adverse event of this regimen as per CTCAE v5.0 criteria. 2. Graft versus host disease-free, relapse-free survival (GRFS) 3. Time to neutrophil and platelet engraftment 4. Incidence of acute and chronic GVHD 5. Relapse incidence 6. Non relapse mortality 7. Overall survival 8. Progression-free survival 9. Chimerism 10. Immunosuppression cessation time 11. Rate of graft failure Exploratory Objective: To conduct mechanistic studies to compare immune recovery between arms and correlate these with disease control and GVHD prophylaxis.